Biotech Investors & VC Firms in Global

911 firms in this list, with a median first check of $500K. 234 of them lead rounds. Generated from verified public data and updated continuously.

Fund	FoxScore	HQ	Invests	Stage	Check	CRM
FA Fast Track Initiative KYNR木廣原泰13 people	88🔒	Tokyo	JP	Pre-Seed–Growth	—	+ Add to CRM
AV Avaana Capital ABSSVVSK18 people · Follows rounds	88🔒	Mumbai	IN	Pre-Seed–Series A	—	+ Add to CRM
TH The March Group CLAHBKBL24 people · Leads rounds	88🔒	Davis	US	Pre-Seed–Seed	—	+ Add to CRM
HB HBM Healthcare Investments AWCPEVET8 people	88🔒	Zug	CH	Growth–Late Stage	—	+ Add to CRM
WO Wormhole Capital NHVG2 people	88🔒	—	US	Pre-Seed–Growth	—	+ Add to CRM
QU Quantonation CJOTWZJM15 people · Leads rounds	88🔒	Paris	FR	Pre-Seed–Growth	—	+ Add to CRM
GS GS Futures ATCAGMHL14 people · Follows rounds	88🔒	Seoul	KR	Pre-Seed–Series A	—	+ Add to CRM
PI Pivotal Life Sciences AKGBPBRH14 people · Follows rounds	88🔒	San Francisco	US	Pre-Seed–Late Stage	—	+ Add to CRM
SI Sixty Degree Capital CKJLKGNX17 people · Follows rounds	88🔒	North York	CA	Pre-Seed–Growth	—	+ Add to CRM
VE Vertex Venture Management Pte. Ltd. KLARCSJL23 people	88🔒	Singapore	SG	Seed–Growth	—	+ Add to CRM
FI First Bight Ventures VBJMAMBZ22 people · Leads rounds	88🔒	Houston	US	Seed–Series A	$1M – $2M	+ Add to CRM
EC Eckuity KMYSASJC24 people	88🔒	Cypress	US	Growth	—	+ Add to CRM
EN Endiya Partners RBSAAKRG9 people · Leads rounds	88🔒	Hyderabad	IN	Pre-Seed–Series A	$2M	+ Add to CRM
TU Tullis Health Investors JTBBDLPM17 people	88🔒	Palm Beach Gardens	US	Series A–Late Stage	$500K – $10M	+ Add to CRM
KI Kilonova Capital KOMWTPWG25 people · Leads rounds	88🔒	San Francisco	US	Growth–Late Stage	$25M – $150M	+ Add to CRM
PH Phoenix Venture Partners FLJMSRAK10 people · Leads rounds	88🔒	San Mateo	US	Seed–Series A	$100K – $3M	+ Add to CRM
SP Speciale Invest ARVRKSVJ11 people · Leads rounds	88🔒	Chennai	IN	Pre-Seed–Seed	$100K – $1M	+ Add to CRM
GD GD1 ASJKNAVK10 people · Leads rounds	88🔒	Auckland	NZ	Pre-Seed–Series B	$150K – $900K	+ Add to CRM
RD RDiscovery TIATKNTK25 people · Leads rounds	88🔒	Tokyo	JP	Pre-Seed–Seed	—	+ Add to CRM
TR TrueLight Capital XYYCCAJH28 people · Follows rounds	88🔒	Singapore	SG	Seed–Late Stage	—	+ Add to CRM
DG DG Incubation	88🔒	—	JP	Seed–Series A	—	+ Add to CRM
TA Tal Ventures EDROGSMS8 people · Follows rounds	88🔒	Tel Aviv	IL	Pre-Seed–Late Stage	—	+ Add to CRM
ME Merck Global Health Innovation Fund BTDSDRJV10 people	88🔒	Rahway	US	Seed–Growth	$10M	+ Add to CRM
MI Miyako Capital TSHOSY三宏14 people	88🔒	Kyoto	JP	Seed–Series B	—	+ Add to CRM

Fast Track Initiative

TokyoPre-Seed–Growth

KYNR木廣原泰13 people

Avaana Capital

MumbaiPre-Seed–Series A

ABSSVVSK18 people

The March Group

DavisPre-Seed–Seed

CLAHBKBL24 people

HBM Healthcare Investments

ZugGrowth–Late Stage

AWCPEVET8 people

Wormhole Capital

Pre-Seed–Growth

NHVG2 people

Quantonation

ParisPre-Seed–Growth

CJOTWZJM15 people

GS Futures

SeoulPre-Seed–Series A

ATCAGMHL14 people

Pivotal Life Sciences

San FranciscoPre-Seed–Late Stage

AKGBPBRH14 people

Sixty Degree Capital

North YorkPre-Seed–Growth

CKJLKGNX17 people

Vertex Venture Management Pte. Ltd.

SingaporeSeed–Growth

KLARCSJL23 people

First Bight Ventures

HoustonSeed–Series A$1M – $2M

VBJMAMBZ22 people

Eckuity

CypressGrowth

KMYSASJC24 people

Endiya Partners

HyderabadPre-Seed–Series A$2M

RBSAAKRG9 people

Tullis Health Investors

Palm Beach GardensSeries A–Late Stage$500K – $10M

JTBBDLPM17 people

Kilonova Capital

San FranciscoGrowth–Late Stage$25M – $150M

KOMWTPWG25 people

Phoenix Venture Partners

San MateoSeed–Series A$100K – $3M

FLJMSRAK10 people

Speciale Invest

ChennaiPre-Seed–Seed$100K – $1M

ARVRKSVJ11 people

GD1

AucklandPre-Seed–Series B$150K – $900K

ASJKNAVK10 people

RDiscovery

TokyoPre-Seed–Seed

TIATKNTK25 people

TrueLight Capital

SingaporeSeed–Late Stage

XYYCCAJH28 people

DG Incubation

Seed–Series A

Tal Ventures

Tel AvivPre-Seed–Late Stage

EDROGSMS8 people

Merck Global Health Innovation Fund

RahwaySeed–Growth$10M

BTDSDRJV10 people

Miyako Capital

KyotoSeed–Series B

TSHOSY三宏14 people

Data sourced from public filings and firms' own websites — see our methodology.